Myopia
Conditions
Interventions
Children and Adolenscents A group:0.01% atropine
Children and Adolenscents B group:1% atropine
Children and Adolenscents C group:Combination use of orthokeratology and 0.01% atropine
Children and Adolenscents D group:Combination use of orthokeratology and 1% atropine
Young Adults A group:0.01% atropine
Young Adults B group:Defocus incorporated multiple segments spectacle lens
Young Adults C group:Combination use of defocus incorporated multiple segments spectacle lens and 0.01% atropine
Young Adults D group:Ordinary glass
Sponsors
Jianfeng Zhu
Eligibility
Sex/Gender
All
Age
8 Years to 29 Years
Inclusion criteria
Inclusion criteria: 1. Progressive myopia in children and adolescents The written informed consent signed by parents (legal representative) and the child himself has been obtained; Age: 8-15 years old; The results of binocular computer optometry after mydriasis met the following requirements: 8-9 years old: - 6.00 d ~ - 2.00 D; 10 years old: - 6.00 d ~ - 3.00 D; 11-12 years old: - 6.00 d ~ - 4.00 D; 13-15 years old: - 6.00 d ~ - 5.00 D. Astigmatism >= - 1.5 D, anisometropia (based on equivalent spherical lens power) = 26mm, astigmatism >= - 1.5D, anisometropia (based on equivalent spherical lens power) <= 1.50D; Pathological myopia was found in fundus photography.
Exclusion criteria
Exclusion criteria: 1. Patients with eye diseases that may affect vision or ametropia (cataract and other lens injury diseases, glaucoma, macular disease, corneal disease, uveitis, retinal detachment, severe vitreous opacity, etc.) history. 2. Patients with systemic diseases: immune system diseases, central nervous system diseases, Down's syndrome, asthma, severe cardiopulmonary function, severe liver and kidney dysfunction. 3. Patients with any eye disease that is prohibited from atropine or other anticholinergic eye preparations. 4. Patients with dominant strabismus or any other pathological changes of the eyeball. 5. Patients with binocular hyperopia whose visual acuity could not be corrected to LogMAR 0.1. 6. Patients who use anticholinergic drugs within one month, such as atropine or pirenzie, and cholinergic drugs such as pilocarpine (except for rapid mydriasis). 7. Patients who used orthokeratology lens, multifocal soft lens and functional frame glasses within 1 month. 8. Patients who are allergic to atropine, cyclopentolate and other drugs used in this study. 9. Patients who have participated in clinical trials of other drugs within 3 months. 10. Other situations considered unsuitable by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Spherical equivalent;axial length; | — |
Secondary
| Measure | Time frame |
|---|---|
| choroidal thickness;choroidal vessel index;retinal vessel density;Peripapillary atrophy; | — |
Countries
China
Contacts
Public ContactJianfeng Zhu
Shanghai Eye Disease Prevention and Treatment Center
Outcome results
None listed